Stocks
Intellia Therapeutics (NTLA) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 1 596% | 4 195% | 1 802% | 719.3% | 3 111% | 7 176% | |||
| Changes by years, y/y, % | +194pp | +2 600pp | -2 394pp | -1 082pp | +2 392pp | +17.3% | |||
Intellia Therapeutics. R&D/CAPEX, %
Intellia Therapeutics. R&D/CAPEX, changes, pp
Intellia Therapeutics (NTLA) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 2 625% | 7 170% | 4 363% | 11 028% | 9 647% | 7 176% | ||
| Changes by years, y/y, % | +343pp | +4 613pp | +1 829pp | +8 348pp | +7 022pp | |||
| Changes by quarters, q/q, % | -56pp | +4 545pp | -2 807pp | +6 666pp | -1 382pp | |||
